- Home
- Products
Besponsa (Inotuzumab Ozogamicin)
Besponsa (Inotuzumab Ozogamicin)
- Medicine Name: Besponsa
- Generic Name: Inotuzumab Ozogamicin
- Dosage Form & Strength: For Injection – 0.9 mg lyophilized powder in a single-dose vial (for reconstitution)
- Manufactured By: Pfizer Inc.
Besponsa is a CD22-targeted antibody-drug conjugate indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Recommended Dosage:
- Cycle 1:
Total dose – 1.8 mg/m² per cycle
Administered as: - Day 1: 0.8 mg/m²
- Day 8: 0.5 mg/m²
- Day 15: 0.5 mg/m²
- Day 1: 0.8 mg/m²
- Cycle duration: 21 days (may extend to 28 days for recovery or remission)
- Subsequent Cycles:
- For patients with CR/CRi: 1.5 mg/m² divided into three doses (0.5 mg/m² on Days 1, 8, and 15)
- For patients without CR/CRi: Same as Cycle 1
- Up to 6 cycles in total
- For patients with CR/CRi: 1.5 mg/m² divided into three doses (0.5 mg/m² on Days 1, 8, and 15)
- Pre-HSCT Patients: Typically receive 2 cycles; a 3rd may be considered if remission isn’t achieved.
Premedication with an antipyretic, antihistamine, and corticosteroid is recommended before each dose.
Infusion-Related Reactions: Patients should be observed during and for 60 minutes post-infusion.
Cytoreduction: Recommended for patients with high lymphoblast counts before starting therapy.
Veno-Occlusive Disease (VOD): Monitor closely for liver toxicity, especially post-HSCT.
Liver Function: Check AST, ALT, total bilirubin, and alkaline phosphatase levels before and after each dose.
Post-Transplant Risks: Increased non-relapse mortality observed in patients proceeding to transplant after Besponsa.
Myelosuppression: Monitor blood counts regularly and assess for signs of infection, hemorrhage, or anemia.
QTc Prolongation: Use caution in patients with QT risk; monitor ECGs and electrolytes as clinically indicated.
Pregnancy Risk: Can cause fetal harm. Women of reproductive age should use contraception during and for 8 months post-treatment. Avoid breastfeeding during this period.
Documents Required to Import Besponsa to India:
- Valid prescription from a registered doctor
- Diagnostic reports
- Patient’s government-issued ID
Availability in India:
Besponsa is a prescription-only medication available for import through the Named Patient Program. Global Rare Meds can facilitate procurement for patients and institutions across India.
Cities We Serve:
Including but not limited to Mumbai, Delhi, Bengaluru, Pune, Chennai, Hyderabad, Ahmedabad, Kolkata, Chandigarh, Jaipur, and Lucknow.
Order Confirmation:
Initiated upon receipt of valid prescription and (if applicable) import authorization.
📧 info@globalraremeds.com
📞 +91-99675 15602 (Call/WhatsApp)
Global Rare Meds sources Besponsa from certified international suppliers across the USA, Canada, Europe, and Australia. Orders are fulfilled from our licensed fulfillment center in Ambernath, Thane District, ensuring:
- Verified quality and batch authenticity
- Cold-chain shipping if needed
- Pharmacist-approved dispensing
- Secure delivery across India and globally
Q: What is the generic name of Besponsa®?
A: Inotuzumab Ozogamicin
Q: Who manufactures Besponsa®?
A: Pfizer Inc.
Q: Is Besponsa® FDA approved?
A: Yes, Besponsa received FDA approval on August 17, 2017.
Q: What dosage forms are available?
A: Lyophilized powder for reconstitution – 0.9 mg in a single-dose vial
Q: What are common side effects of Besponsa®?
A: Fatigue, thrombocytopenia, neutropenia, fever, infection, anemia, nausea, hemorrhage, and liver enzyme elevations.
Q: What are the storage conditions?
A: Store in the original carton at 2°C to 8°C (36°F to 46°F). Do not freeze. Follow cytotoxic handling guidelines for safe use and disposal.
Q: What is the cost of Besponsa® in India?
A: Prices vary based on supplier and availability. Contact info@globalraremeds.com or call/WhatsApp +91-99675 15602 for pricing.
Q: Can I legally import Besponsa® into India?
A: Yes, with valid medical documentation, Global Rare Meds can help you legally procure Besponsa through regulated import channels.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
